Introduction
============

The expansion of the cerebral cortex is a major hallmark of mammalian evolution, particularly in the primate lineages where it achieves its greatest complexity in humans ([@B129]). Despite great variation in size, there are many similarities in the structure and function of the cerebral cortex across all mammalian species. These similarities have encouraged neuroscientists to use relatively simple cortices, such as those of rodents, as models in which to investigate biological processes and mechanisms with likely relevance to humans. The strength of rodent models, in particular mice, derives in large part from the genetic and transgenic approaches that can be used to study molecular mechanisms. Much of the research described in this review comes from studies of mice and the view of cortical development and Pax6's role in that process presented here is strongly biased toward mouse corticogenesis. It is important to recognize, however, that significant differences exist between the developing and mature cortices of primate and non-primate species that are more than just differences of scale, and we shall highlight some of these. It is remarkable that many high-level regulatory genes such as *Pax6* are themselves extremely highly conserved between primates and non-primates although they influence and control aspects of cortical development that differ: for example, the amino acid sequences of human PAX6 and mouse Pax6 are identical ([@B197]) although Pax6's expression in primate embryos extends to cortical structures that do not exist in mice. This implies that evolutionary changes in the functions of these regulators have been achieved by changes in the mechanisms regulating their expression and in the ways in which the downstream molecular networks respond to them, but we know almost nothing about these evolutionary changes at a molecular level.

The cerebral cortex is derived from the dorsal component (or pallium) of the embryonic telencephalon, which is itself the anterior-most subdivision of the forebrain ([@B97]). The cerebral cortex can be further sub-divided into distinct regions, including the neocortex, a novel acquisition of mammals that has evolved between the phylogenetically older archicortex (comprising entorhinal cortex, retrosplenial cortex, subiculum, and hippocampus) and paleocortex (olfactory piriform cortex). The evolutionary expansion of the neocortex is thought to account for much of the increase in overall brain size and complexity in more advanced species ([@B109]; [@B150]). The neocortex (hereafter referred to simply as cortex) contains an extraordinarily large number of neurons arrayed in a six-layered sheet, with neurons in each layer organized into a complex network of local circuits and subcortical connections. In primates, some of these layers are subdivided in some cortical areas: for example, in primary visual cortex, layer 4 is subdivided into layers 4a, b, and c. The primate cortex is also characterized by an expansion of the superficial layers of the cortex, layers 2 and 3 (also known as the supragranular layers), which have an important function in the transfer of information between cortical areas. Increased intracortical information processing is likely to have contributed to heightened cognitive ability. In all mammals, the cortex comprises two major groups of neurons: the majority are excitatory glutamatergic projection neurons (70--80%), which exhibit a characteristic pyramidal morphology and extend axons to distant intracortical, subcortical, and subcerebral targets; a minority are inhibitory GABAergic non-pyramidal interneurons (25--30% in primates, 15--20% in rodents), which have short axons and project locally ([@B80]; [@B12]). An appropriate balance between the excitatory and inhibitory circuitry of the cortex is critical for its normal function.

*Pax6* is a pivotal gene in CNS development. It is expressed when the major components of the developing CNS first emerge after neural tube closure and its expression patterns change considerably as major structures such as the cerebral cortex specialize and expand. Its expression plays a major role in the subsequent development of the regions that continue to express it. In this review we shall discuss how Pax6 plays critical roles in aspects of corticogenesis that include the early patterning of telencephalic subdivisions, control of cortical cell number, normal cortical layer formation and the development of the correct balance of excitatory and inhibitory neurons. We shall review what is known about the upstream control of *Pax6*'s transcription, the molecular basis of its functions and its actions on genes downstream of it and the cellular processes they regulate.

Corticogenesis in Rodents and Primates and the Cortical Expression of Pax6
==========================================================================

The closure of the neural tube is accompanied by its disproportionate expansion anteriorly to generate the early forebrain. The earliest cortical progenitors undergo symmetric proliferative divisions at the ventricular surface to amplify a pool of progenitors, an increasing proportion of which then divide asymmetrically to regenerate progenitors and to produce other cell types including neurons.

In mouse, the generation of excitatory cortical neurons occurs between embryonic day 11 (E11) and E18 ([@B63]; [@B160]; [@B113]). Their progenitors are located in one of two pallial germinal epithelia, namely the ventricular zone (VZ), which lies adjacent to the ventricles, and the subventricular zone (SVZ), which lies just above the VZ (**Figure [1](#F1){ref-type="fig"}**). The early symmetrically dividing cortical neuroepithelial cells (NECs) that each produce two daughter NECs per division and whose population rapidly expands laterally and radially, transform into another type of progenitor called, for historical reasons, radial glial cells (RGCs; **Figure [1](#F1){ref-type="fig"}**). RGCs, whose long processes span the neuroepithelium, have been known for a long time to provide guidance for migrating neurons ([@B114]; [@B164]; [@B73]; [@B193]). Despite having morphological and molecular features associated with glial cells, they are progenitors capable of generating other types of progenitor, neurons and glial cells ([@B122], [@B121]; [@B137]; [@B147]; [@B183]; [@B79]; [@B193]). RGCs constitute the majority of the VZ progenitor population. They are often referred to as apical progenitors (APs) due to the location of their cell body close to the ventricular or apical surface of the VZ, to which they extend a short process while sending a longer basal process radially to the pial surface of the cortex ([@B24]; [@B14]; [@B193]). As they progress through the cell cycle, RGCs undergo interkinetic nuclear migration. Their nucleus migrates radially through the cytoplasm such that mitosis occurs at the apical ventricular surface and S-phase at a basal position in the VZ. While at early stages of corticogenesis RGCs predominantly self-renew via symmetric divisions, they progressively switch to asymmetric divisions, which produce one daughter RGC and one daughter cell with a heightened level of commitment ([@B147], [@B148]; [@B77]; [@B87]; [@B193]). The differentiating daughter cell either migrates radially to the pial surface and differentiates into a neuron or migrates to the SVZ to become an intermediate progenitor cell (IPC), also called a basal progenitor (BP) or basal IPC (bIPC; **Figure [1](#F1){ref-type="fig"}**; [@B74]; [@B138]; [@B148]). BPs accumulate in the SVZ and divide mainly symmetrically to generate two neurons. It is thought that most cortical projection neurons are generated by BPs ([@B52]). In addition to RGCs, the VZ contains another smaller subpopulation of APs called short neural precursors (SNPs), also known as apical IPCs (aIPC; **Figure [1](#F1){ref-type="fig"}**). Unlike RGCs, aIPCs do not self-renew and only generate pairs of neurons via symmetric divisions ([@B58]; [@B193]).

![Cortical germinal areas of rodents and primates. Coronal section through the developing cortex of a rodent and a primate showing progenitor types and whether they express Pax6 and/or Tbr2. CP, cortical plate; SP, subplate; IZ, intermediate zone; SVZ, subventricular zone; ISVZ, inner subventricular zone; OSVZ, outer subventricular zone; VZ, ventricular zone; aRG, apical radial glia; bRG, basal radial glia; aIPC, apical intermediate progenitor cell; bIPC, basal intermediate progenitor cell.](fncel-09-00070-g001){#F1}

Significant progress in understanding the mechanisms underlying corticogenesis has been made through analysis of gene expression in both progenitor cells and post-mitotic neurons. Such studies have revealed a crucial role for transcription factors (TFs) as molecular markers of distinct progenitor and neuron types and as key regulators of progenitor cell proliferation and cell fate decisions. At the onset of neurogenesis, TFs including Pax6, Emx2, and Tlx expressed in the cortical neuroepithelium function mainly to influence areal patterning and regulate progenitor cell proliferation ([@B20], [@B21]; [@B144]; [@B145]; [@B186],[@B187]; [@B81]). As neurogenesis proceeds, a large number of TFs are involved in regulating the balance between progenitor cell proliferation and neuronal differentiation. Regulating this balance is essential for the generation of the correct proportions of different classes of neurons and subsequent circuit assembly.

During the neurogenic period in the mouse cortex, Pax6 is expressed by VZ APs in a high rostro-lateral to low caudo-medial gradient (**Figures [2](#F2){ref-type="fig"}** and **[3](#F3){ref-type="fig"}**). As well as being graded spatially, the expression of Pax6 is also graded temporally, with highest levels present at the onset of corticogenesis. APs that give rise to BPs transiently express the proneural TF Neurogenin 2 (Ngn2; [@B22]). Pax6 is not expressed in BPs which are characterized by their expression of another TF, Tbr2, or in post-mitotic neurons which express Tbr1 (**Figure [1](#F1){ref-type="fig"}**; [@B48]). Thus a sequential Pax6 → Ngn2 → Tbr2 → Tbr1 expression correlates with the transition of APs to BPs to post-mitotic neurons.

![The gradient expression pattern of Pax6 protein in the mouse developing cortex. **(A)** A schematic diagram shows the Pax6 protein (red) is normally expressed in a ^high^rostrolateral to ^low^caudomedial gradient in the developing cortex during early cortical development. **(B,C)** immunofluorescence staining for Pax6 protein in sagittal section **(B)** and coronal section **(C)** from E12.5 mouse WT embryos (scale bars, 100 μm).](fncel-09-00070-g002){#F2}

![Comparison of Pax6 expression in embryonic human and mouse cortex. Images from human cortices at 8, 10, and 12 post-coital weeks (PCWs) were generated using material from the Human Developmental Biology Resource ([www.hdbr.org](http://www.hdbr.org)) as part of the HuDSeN ([@B96]) human gene expression spatial database (<http://www.hudsen.org>) based at Newcastle University. PAX6 is expressed in the ventricular zone (VZ) and subventricular zone (SVZ) at 8 PCW. The SVZ divides into an outer and an inner subventricular zone (OSVZ and ISVZ), both of which continue to express PAX6. In mice, Pax6 expression is confined almost exclusively to the VZ during corticogenesis, as shown here at embryonic days (E) 13.5, 15.5, and 17.5. Additional abbreviations: CP, cortical plate; IZ, intermediate zone.](fncel-09-00070-g003){#F3}

In the macaque cortex, [@B163] showed that cortical neurogenesis occurs between E45 and E100. Gestation in this species lasts 165 days and so cortical neurons are generated relatively earlier in gestation in primates than in rodents. The primate SVZ forms earlier and shows a much greater expansion than in rodents, becoming the predominant progenitor zone by mid-corticogenesis ([@B184]). It is split into the inner and outer SVZs separated by an inner fiber layer ([@B184]; [@B118]; [@B224]; [@B53]; [@B72]; [@B54]). The inner subventricular zone (ISVZ) contains mainly IPCs similar to those in the rodent SVZ whereas the outer subventricular zone (OSVZ) contains mainly basal RGCs (bRGCs) similar to the APs present in the rodent VZ (**Figure [1](#F1){ref-type="fig"}**). bRGCs undergo proliferative divisions and self renewing asymmetric divisions to generate one bRGC daughter cell and one IPC that can proliferate further ([@B53]; [@B72]; [@B54]). bRGCs have also been observed in the rodent SVZ but, while they constitute about half of all progenitors present in the primate SVZ, they account for only a minute fraction of the SVZ progenitors in rodents (**Figure [1](#F1){ref-type="fig"}**). The OSVZ is the major source of supragranular layer neurons ([@B112]; [@B118]).

The sequential Pax6 → Ngn2 → Tbr2 → Tbr1 expression that correlates with the AP → BP → post-mitotic neuron transition in mice is not found during primate corticogenesis. In contrast to rodents, Pax6 is expressed by progenitors in the VZ, ISVZ, and OSVZ in primates (**Figure [3](#F3){ref-type="fig"}**; [@B53]; [@B19]; [@B54]) and many progenitors co-express Pax6 and Tbr2 (**Figure [1](#F1){ref-type="fig"}**). In the macaque, the majority of VZ progenitors (60--80%) express only Pax6 during early and mid-stages of corticogenesis (up to E79), but at later stages (after E79) 40% of them co-express Tbr2 ([@B19]; [@B54]; **Figure [1](#F1){ref-type="fig"}**). In the ISVZ, 60--80% of progenitors co-express Pax6 and Tbr2, 5--30% express only Tbr2 and less than 15% express only Pax6. In the OSVZ, Pax6, and Tbr2 are co-expressed by 25--50% of progenitors while 20--35% express only Pax6 and 10--20% only Tbr2 (**Figure [1](#F1){ref-type="fig"}**; [@B19]; [@B54]).

In mice, cortical GABAergic interneurons originate from distant germinal domains in the ganglionic eminences and follow tangential migratory routes to reach the developing cortex ([@B59]). In primates, the origin of cortical interneurons is controversial. It has been proposed that while many interneurons have a ventral telencephalic origin, a significant fraction are produced in the progenitor layers of the cortex itself during the second half of corticogenesis ([@B112]; [@B224]; [@B154]; [@B88]). However, a recent study by [@B71] found no evidence of interneuron production in the cortical wall. Instead, their analysis suggests that, as in rodents, the vast majority of human cortical interneurons are produced in the ganglionic eminences ([@B71]).

In all mammalian species, the positions adopted by neurons migrating from the cortical progenitor zones to the overlying developing cortical plate (CP) are related to their birthdate. Each successive generation of newly born projection neurons bypasses earlier-born neurons and settles close to the pial edge of the CP. Thus, cortical layers (with the exception of layer 1) are formed in a deep-first superficial-last sequence ([@B5]; [@B16]; [@B163]; [@B131]; [@B193]). When projection neurons arrive in their final laminar positions, they undergo terminal differentiation including elaboration of their dendrites and axons to establish connections and eventually form the cortical circuitry. Projection neurons in each layer tend to exhibit similar gene expression patterns, morphologies and organization of afferent and efferent connections ([@B188]).

Human Brain Disorders Associated with *PAX6* Mutations
======================================================

In humans, heterozygous loss-of-function mutations of *PAX6* cause sight-threatening congenital eye defects, typically including severe hypoplasia of the iris (aniridia) and retina. These mutations are also associated with a range of neurological and psychiatric conditions including nystagmus, impaired auditory processing and verbal working memory, autism, and mental retardation ([@B120]; [@B11], [@B9],[@B10]; [@B40]; [@B82]; [@B119]). These conditions are linked to structural brain defects including reduced size of the corpus callosum and anterior commissure, abnormalities of the cerebral cortex and cerebellum and absence of the pineal gland ([@B182]; [@B56]; [@B136]; [@B11], [@B10]; [@B47]).

Only four cases of children with mutations in both *PAX6* alleles (compound heterozygotes) have been reported ([@B64]; [@B172]; [@B185]). Two of them survived past birth, one only for about 1 week ([@B64]), the other until at least 4 years ([@B185]). The former had anophthalmia, the latter microphthalmia, and both had numerous defects in the CNS including agenesis of the corpus callosum and microcephaly. [@B64] described a disturbed stratification of the cerebral cortex with heterotopic islands of germinal and ependymal cells, as well as focal polymicrogyria of the cerebral cortex. Two other cases were sibling fetuses with the pregnancies terminated at 21 and 23 weeks ([@B172]). In both cases the brain was very small, filling only 1/3 of the cranial cavity, and displayed completely disorganized structures of the brain hemispheres and cerebellum. Microscopic analysis showed that the cerebral hemispheres contained an enormous amount of germinal matrix both in the inner parts and at the surface of the hemispheres. The cortex was very narrow with a paucity of cells with an irregular distribution of large neurons. The structure of the cortex was disturbed with a thick layer of germinal cells on its surface, a poorly defined marginal zone and no normal stratification. In the entire cortex the cells were mainly in clusters. The development of the white matter was also severely disturbed. The intermediate zone was absent. In several places of the cortex and also between clusters of neuroblasts inside the brain hemispheres there were fascicles of axons which did not form normal tracts. The heterotopia of germinal cells observed in the human compound heterozygotes (**Figure [4A](#F4){ref-type="fig"}**) are reminiscent of the clusters of germinal cells found in the intermediate zone of the cortex of *Pax6^-/-^* mouse embryos (**Figure [4B](#F4){ref-type="fig"}**; [@B25]). In these Pax6 mutant embryos it is thought that the clusters form as a consequence of a cell non-autonomous migration defect ([@B25]).

![Histology of *Pax6^-/-^* developing cortex in human and mouse. **(A)** Coronal section through the cortex of a fetus with a compound heterozygosity for two *PAX6* mutations showing a layer of germinal cells on the surface of the cortex (arrow) and heterotopia of germinal cells within the cortex (arrowhead). Photograph taken from [@B172]. **(B)** Coronal section through the cortex of a *Pax6^-/-^* mutant mouse embryo showing clusters of germinal cells in the intermediate zone (arrowhead). Photograph from [@B25].](fncel-09-00070-g004){#F4}

Structure and Transcriptional Regulation of the *Pax6* Locus
============================================================

In both human and mouse, the *Pax6* gene has 16 exons distributed over a 30 kb genomic region including alternatively spliced exons *alpha* and 5a ([@B65]; [@B210]; [@B95]; [@B157]; [@B218]). Four transcription start sites have been identified in mouse *Pax6*, associated with the P~0~, P~1~, P*~alpha~*, and P~4~ promoters respectively (**Figure [5](#F5){ref-type="fig"}**; [@B95]; [@B218]; [@B100]; [@B142]). Transcriptional regulation of the *Pax6* locus is particularly complex. A number of short-range regulatory elements have been identified in the vicinity of the *Pax6* coding region which control tissue-specific *Pax6* expression (**Figure [5](#F5){ref-type="fig"}**; [@B95]; [@B158]; [@B103], [@B100]; [@B68]). Some of these elements exhibit overlapping tissue specificity, particularly in the eye, telencephalon and diencephalon, suggesting that they exert functions through cooperative interactions.

![Structure and transcriptional regulation of the *PAX6* locus. Schematic map of human chromosome 11p13 shows the locations of the PAX6 and ELP4 loci, which are in an antisense orientation relative to each other. The locations of PAX6 promoters (P0, P1, Pa, and P4) are indicated by black arrows. Blue rectangles indicate *PAX6* exons, while black rectangles below the line indicate *ELP4* exons. The known highly conserved regulatory elements, such as E60, E100 and RB, are indicated by purple ellipses. The breakpoints of the two distal-most aniridia-associated rearrangements are indicated by "SGL" and "SIMO." The location of the downstream regulatory region (DRR) is shown by red arrows. The known DNaseI hypersensitive sites (HS sites) within the DRR region are shown by red arrows. The schematic maps of YACs Y593 (420 kb) and Y589 (310 kb) are indicated. In transgenic mice, Y593, but not Y589, rescues the mouse *Sey* phenotype and homozygous *Sey* lethality.](fncel-09-00070-g005){#F5}

Although these short-range regulatory elements account for much of *Pax6*'s normal expression pattern in mice, genetic analyses in both humans and mice revealed that they are insufficient to drive the full pattern of *Pax6* expression, particularly in the eye and forebrain ([@B98]; [@B102]; [@B130]). The first evidence that PAX6 expression is influenced by distant regulatory elements located far downstream of *PAX6*'s coding exons came from studies of aniridia patients, a subset of which harbor chromosomal rearrangements whose breakpoints are located far downstream of the *PAX6* transcriptional unit ([@B57]; [@B51]; [@B110]; [@B103]; [@B33]). The most distant of these breakpoints, designated "SIMO,\" is located 124 kb downstream of the *PAX6* polyadenylation site ([@B51]; [@B103]; **Figure [5](#F5){ref-type="fig"}**). The functional importance of regulatory regions around distant breakpoints was confirmed by the finding that a yeast artificial chromosome (YAC) comprising 420 kb of the human *PAX6* coding sequence and flanking regions stretching beyond the SIMO breakpoint rescues the mouse *small eye* (*Sey*) phenotype, whereas a YAC transgene with 110 kb less DNA sequence at the 3^′^ end fails to rescue ([@B103]). Subsequent analyses revealed the presence of essential 3^′^ distant regulatory elements within a 75 kb region termed the *PAX6* downstream regulatory region (DRR) located 3^′^ of the SIMO breakpoint (**Figure [5](#F5){ref-type="fig"}**; [@B170]; [@B103]; [@B130]). A number of other conserved regulatory elements, including E60, E100, and RB (**Figure [5](#F5){ref-type="fig"}**), located either upstream or downstream of the DRR region are thought to be crucial for the induction of *PAX6* expression in the eye and forebrain ([@B68]; [@B101], [@B102]; [@B98]; [@B130]).

We recently reported a detailed examination of a series of novel transgenic reporter mice lines, carrying versions of either the full length 420 kb YAC described above or truncated versions that lacked putative regulatory elements. The YAC transgenes were modified by the introduction of a tau-GFP reporter cassette into the first coding exon of *PAX6*, such that GFP expression marks cells in which the transgenes are expressed. We found that regulatory elements that lie outside the 420 kb YAC transgene are required for correct *PAX6* expression in sub-regions of the telencephalon and diencephalon, indicating that recapitulation of the full *PAX6* expression pattern requires even more elements than had previously been thought ([@B134]).

The *Pax6* locus is subject to autoregulation -- *Pax6* has been shown to regulate its own expression. Putative Pax6 binding sites have been identified in *Pax6* regulatory elements in several species. For example, in *Drosophila*, two intronic enhancer elements containing putative Pax6 binding sites mediate auto-activation of *eyeless* (a *Drosophila Pax6* homolog) in the nervous system and eye ([@B76]). These elements may serve the same function in vertebrates as they exhibit significant sequence identity between *Drosophila* and vertebrate species ([@B31]). In addition, Pax6 directly interacts with putative Pax6-responsive elements within the head surface ectoderm-specific enhancer of mouse *Pax6*, positively regulating its own transcription ([@B6]). Similarly, Pax6 autoregulation in the forebrain was revealed through the identification of a highly conserved regulatory element (CE2) in intron 7 of mouse *Pax6* (**Figure [5](#F5){ref-type="fig"}**). Overexpressing either Pax6 or its alternative spliced isoform Pax6(5a) positively autoregulated expression of the endogenous *Pax6* locus in Neuro2D and NIH3T3 cell lines ([@B156]). The *Pax6* locus is also subject to negative autoregulation, whereby Pax6 represses transcription of the *Pax6* locus, as shown in the developing telencephalon ([@B126]). In summary, these studies highlight the fact that appropriate levels of Pax6 expression are regulated by both positive and negative autoregulation during development.

Pax6 Regulates Cell Cycle Length and Cell Cycle Exit
====================================================

Generating the correct number of cortical neurons of the correct types involves changes in both the mode of division of cortical progenitors and length of their cell cycle. As discussed above, cortical progenitors switch progressively from proliferative symmetrical divisions to differentiative asymmetrical divisions during corticogenesis. At the same time, the length of the cell cycle in AP cells in mouse cortex increases from 8 h at the onset of neurogenesis (E10) to 18 h at the end (E18), largely due to lengthening of the G1 phase ([@B191], [@B192]; [@B50]). Subsequent studies showed that G1 lengthening acts to promote the genesis of BP cells which have much longer cell cycle length (around 26 h in E14.5 mouse cortex) due to increase in the G1 length ([@B7]). In the macaque, AP cell cycle length is much longer than in rodents and it follows a different developmental course ([@B105]). It lengthens linearly from 23 h at E40 to 54 h at E60, then shortens linearly to 27 h by E80 ([@B105]). As the neurogenic period is 10 times longer than in rodents, macaque cortical progenitors undergo many more rounds of division even though the duration of the cell cycle is longer ([@B105]), generating a greater number of cortical cells and a larger cortex.

There is mounting evidence that TFs exert region-specific control of cortical progenitor cell cycle progression. Pax6 is one of a number of TFs that are expressed in distinct gradients across cortical areas ([@B223]; [@B168]; [@B166]; [@B61]) and several studies have implicated Pax6 in the temporal and spatial control of cell cycle duration in cortical progenitors. Loss of Pax6 during early cortical development (E12.5) in mice *in vivo* led to a shortening of the cell cycle of progenitors coupled with higher proportions of asymmetrical divisions, resulting in a temporary increase in the production of post-mitotic neurons ([@B208]; [@B50]; [@B206]). Experiments with cultured *Pax6^-/-^* mutant cortical cells showed that they too exhibit accelerated proliferation, indicating that Pax6's effects on the cell cycle are cell autonomous ([@B50]). In contrast, at the mid-corticogenesis stage (E15.5) *Pax6^-/-^* progenitor cells proliferated more slowly than wild type controls, showing that the effects of Pax6 on the cell cycle of cortical progenitors are context-dependent.

Gain of function studies also support the idea that Pax6 controls cell cycle progression. For example, forced expression of Pax6 impairs progenitor cell proliferation *in vitro* ([@B79]; [@B70]; [@B27]). In *PAX77* mice, which express PAX6 protein in its normal pattern but at approximately double the wild type level, there is a reduction in the number of proliferating progenitors in the rostral and central cortex, the areas where levels of Pax6 expression are normally highest ([@B126]). Further, APs located in rostral cortical areas proliferate more slowly in these mice ([@B61],[@B62]). Thus, both gain and loss of Pax6 function studies have revealed powerful context-specific effects of Pax6 on the cell cycle of progenitor cells in a variety of cortical areas and stages.

Early in corticogenesis, expression levels of Pax6 vary between different cortical regions but its expression levels become increasingly uniform with embryonic age ([@B125]; [@B189]; [@B126]). Some of the evidence cited above indicates that the actions of Pax6 on the cell cycle of cortical progenitors are associated with its expression levels. This assumption is strongly supported by our recent study in which cell cycle parameters were systematically examined in different cortical regions at different developmental stages using mouse models with either constitutive or conditional loss of Pax6 function ([@B133]). During early corticogenesis (E12.5), when the Pax6 gradient is steepest, areas of highest expression correlate with regions where the cell cycle duration is longest (**Figure [6](#F6){ref-type="fig"}**). Loss of Pax6 causes shortening of the cell cycle only in these areas (**Figure [6](#F6){ref-type="fig"}**). In normal embryos at older ages, the Pax6 gradient becomes progressively more uniform across the cortex, as does cell cycle length, and loss of Pax6 causes shortening of the cell cycle in all areas (**Figure [6](#F6){ref-type="fig"}**; [@B133]). Taken together, these studies indicate that Pax6 primarily exerts a repressive action on the cell cycle progression of cortical progenitors, and distinct expression levels of Pax6 confer its region and age -specific role in regulating progenitor cell proliferation.

![Effect of loss of Pax6 on cortical progenitor cell cycle parameters. Diagram showing the cell cycle length and S-phase length of cortical progenitors at a rostral or caudal position in Wild type or *Pax6^-/-^* embryos. At E12.5 Pax6 is normally expressed in a high rostral to low caudal gradient and loss of Pax6 results in a shortening of the cell cycle rostrally with no effect on S-phase length. At E14.5 Pax6 is expressed in a flatter rostro-caudal gradient and loss of Pax6 causes a shortening of the cell cycle both rostrally and caudally while the S-phase length remains unaffected.](fncel-09-00070-g006){#F6}

As well as regulating the length of the cell cycle in cortical progenitors, Pax6 is involved in the control of cell cycle exit. In the *Pax6^sey/sey^* mutant cortex, the number of progenitor cells that exit the cell cycle during early corticogenesis (E12.5) is increased, leading to a smaller progenitor pool and an increased proportion of newborn neurons ([@B50]; [@B162]). A similar effect has been seen in the eye and the spinal cord, where loss of Pax6 caused precocious neuronal differentiation due to premature cell cycle exit ([@B155]; [@B13]). Interestingly, a study using *PAX77* mice revealed that increasing Pax6 levels also causes an increase in the proportion of progenitor cells exiting the cell cycle during late corticogenesis (E15.5; [@B62]), indicating that there is no simple dosage-dependent relationship between Pax6 level and progenitor cell cycle exit rate. Recently, we found that loss of Pax6 led to fewer progenitors exiting the cell cycle at the PSPB (pallial--subpallial boundary) at E12.5, the area of the telencephalon where Pax6 expression is highest, contrasting with the previous finding that *Pax6^-/-^* cortical progenitors show increased cell cycle exit at E12.5 ([@B50]). It appears that, although a general function of Pax6 is to influence cell cycle exit, the exact nature of its effect depends on the molecular and cellular context within which it acts. This context may change corresponding to diverse Pax6 levels in different regions at different developmental stages. In support of this assumption, a number of independent analyses demonstrated that Pax6 exerts different control functions on progenitor proliferation in different cellular contexts: Pax6 enhances proliferation in the neural retina of vertebrates ([@B127]) and *Drosophila* ([@B42]), whereas it inhibits proliferation of human glioblastoma cells ([@B227]), cultured corneal epithelial cells ([@B152]) and cortical progenitors in primary cell cultures ([@B79]; [@B75]) as well as *in vivo* ([@B50]; [@B15]). Therefore, it is difficult to conclude a simple universally consistent role of Pax6 in the regulation of cell cycle exit.

Pax6 Direct Targets Regulating Progenitor Cell Proliferation
============================================================

As described above, Pax6 is important for the regulation of cortical progenitor proliferation ([@B50]; [@B126]; [@B162]; [@B62]; [@B133],[@B134]). Cell cycle progression is driven by the concerted action of cyclin-dependent kinases (Cdks) and their activating partners, cyclins ([@B124]). Low levels of Cdk activity are sufficient for cells to transit from G1 into S phase, whereas high-levels of Cdk activity are required for the cell to undergo mitosis ([@B41]; [@B93]). During G1, cells integrate and respond to extracellular cues that either allow the cell to continue cycling or promote its withdrawal from the cell cycle and begin differentiation ([@B225]). Progression through G1 is mainly driven by the activation of Cdk4/6 and their activating partners, D-type cyclins (Cyclin D1 and D2) as well as Cdk2 and its partner Cyclin E ([@B123], [@B124]). Cdk activity is negatively regulated by members of the cyclin-dependent kinase inhibitors family (CKIs; [@B159]; [@B175]; [@B204]). The primary substrate of Cdks during G1 phase is the retinoblastoma protein (pRb). pRb acts as a repressor of E2F TFs through direct interaction. In quiescent cells, the activities of E2Fs are repressed through direct interaction with hypophosphorylated pRb. In cycling cells, mitogenic stimuli that elevate Cyclin levels promote pRb phosphorylation by Cyclin/Cdk complexes, which in turn prevents pRb from binding to E2Fs. Consequently, pRb/E2F complexes are dissociated and free E2Fs are now active and ready to drive the transcription of genes encoding proteins that are involved in G1 phase progression and DNA replication. Gene expression profiling studies showed that Pax6 is capable of regulating the expression of a number of cell cycle genes involved in G1 to S phase transition, such as *Cdk4, Cdk6, Ccnd1, Ccnd2, p27^*kip1*^, Cdc6, Mcm3, Mcm5, Mcm6, Cdca2* and*Cdca7*, with many of them being repressed by Pax6 ([@B167]; [@B133],[@B134]). These findings are in line with the notion that Pax6 mainly acts as an important regulator of progenitor cell proliferation during early cortical development as reviewed above. Among the cell cycle genes whose expression is regulated by Pax6, Pax6 direct targets identified to date include *Cdk4*, *Cdk6*, *Mcm3*, *Cdca2*, *Cdca7,* and p27^*kip1*^ (**Table [1](#T1){ref-type="table"}**; [@B45]; [@B167]; [@B133],[@B134]).

###### 

Genes that have been identified as direct Pax6 targets in the mouse developing cortex grouped according to the developmental process that they affect.

  Process                    Gene            Approach   Reference                       
  -------------------------- --------------- ---------- ----------- --- --- --- --- --- ------------------
  Cell fate specification    *Etv1 (Er81)*   X                      X   X       X       [@B202], [@B167]
                             *Olig2*                    X                   X           [@B89]
                             *Isl1*          X                      X                   [@B167], [@B216]
                             *Foxd1*         X                      X                   [@B167]
  Basal progenitor genesis   *Neurod1*       X                      X                   [@B167]
                             *Gadd45g*       X                      X                   [@B167]
                             *Tbr2*          X          X           X               X   [@B167], [@B199]
  Neurogenesis               *Ngn2*          X                      X   X       X       [@B169], [@B167]
                             *Sox4*          X                      X                   [@B167]
                             *Sox11*                    X           X                   [@B146]
                             *Pou3f4*                   X           X                   [@B146]
                             *Nfib*                     X           X                   [@B146]
                             *Cux1*                     X               X           X   [@B199]
                             *Tle1*                     X               X           X   [@B199]
  Cell cycle                 *Cdk6*                     X               X   X           [@B133]
                             *Cdk4*          X                      X                   [@B167]
                             *Mcm3*          X                      X                   [@B167]
                             *Cdca2*         X                      X                   [@B167]
                             *Cdca7*         X                      X                   [@B167]
                             *P27^*kip1*^*              X                           X   [@B45]
  Cell proliferation         *Pten*          X                      X                   [@B167]
                             *Cdh1*          X                      X                   [@B167]
                             *Lix1*          X                      X                   [@B167]
                             *Hmga2*         X                      X                   [@B167]
                             *Fgfr1*         X                      X                   [@B167]
  Axonal transport           *Kif1b*         X                      X       X           [@B216]
  Unknown                    *Snca*          X                      X                   [@B216]

It is interesting to note that in addition to its repressive effect, Pax6 can also activate expression of some cell cycle genes ([@B86]; [@B151]; [@B167]; [@B133],[@B134]; [@B216]). For example, Pax6 directly promotes the expression of *Cdk4* in neural stem cells in early cortical development ([@B167]). This supports the concept that Pax6 has dual roles to both promote and inhibit cell proliferation in the developing cortex, possibly through the divergent functions of its DNA-binding subdomains (see below; [@B206]). Using transcriptome analysis of the cortex in embryos with either gain and loss of Pax6 function, [@B167] showed that Pax6 regulates a core transcriptional network that controls cortical neural stem cell proliferation in a dosage-dependent manner. They found that under normal conditions *in vivo*, Pax6 has the potential to both promote and inhibit stem cell proliferation by exhibiting opposing effects on the expression of different sets of cell cycle genes, but when Pax6 levels are increased, as in transgenic cortex overexpressing Pax6, the neurogenic functions of Pax6 are dominant over its ability to promote proliferation. This study is in line with our finding that at the onset of corticogenesis, the repressive effect of Pax6 on progenitor cell proliferation and the Cdk/Cyclin mediated phosphorylation of pRb is localized to regions of cortex where Pax6 expression is normally highest, indicating a relationship between the level of Pax6 expression and its anti-proliferative effect ([@B133]). Given that Pax6 is expressed in a gradient during early cortical development, the dosage-dependent effects of Pax6 on cell proliferation are important in the context of understanding how the cerebral cortex becomes divided into regions with specific cytoarchitectures and functions.

Pax6 is an Intrinsic Determinant of Neuronal Fate in the Developing Cortex
==========================================================================

The observations that Pax6 is specifically expressed by radial glial progenitor cells in the developing cortex and is required for them to acquire their normal morphology, gene expression pattern and cell cycle characteristics ([@B66]), suggested that Pax6 may control their ability to generate neurons. To address this question, [@B79] used a combination of loss and gain of function approaches. They found that cultured RGCs isolated from the developing cortex of *Pax6^-/-^* mutant mouse embryos generated half as many pure neuronal clones as RGCs from control embryos. Using a tau-GFP transgene to label and quantify neurons by fluorescence activated cell sorting (FACS), they showed that the number of neurons in the cortex of *Pax6^-/-^* mutant mouse embryos was reduced by half at E14.5 and by a third at E16.5 compared to controls, consistent with the previously reported thinner CP in *Pax6^-/-^* cortex ([@B171]). Forced expression of Pax6 in cells dissociated from E14 cortex or in astrocytes from postnatal cortex, via transduction of a retroviral vector containing full length Pax6 cDNA, resulted in a significant increase in the number of pure neuronal clones generated, demonstrating that Pax6 is an intrinsic determinant of neuronal fate in murine cortical progenitors ([@B79]). [@B140] showed that siRNA-mediated knockdown of Pax6 expression in cultured human fetal RGCs led to a significant decrease in the number of neurons produced, suggesting that the role of Pax6 in cortical neurogenesis is maintained from rodents to humans ([@B140]).

Pax6 Confers both Regional and Neurotransmitter Fates
=====================================================

The mammalian CP comprises mainly glutamatergic neurons born in the cortical VZ and GABAergic interneurons (INs). In mouse, most INs are born in the medial ganglionic eminence (MGE; ∼70%) with others coming from the caudal ganglionic eminence (CGE) and areas including the preoptic area (POA; [@B4]; [@B213]; [@B55]; [@B60]; [@B139]). INs born in the LGE populate the olfactory bulb (OB) and the ventral telencephalon. Most cortical glutamatergic neurons and GABAergic interneurons are generated between E12.5 and E16.5. By E18.5, GABAergic INs are distributed throughout the cortex of wild type embryos. In contrast, the cortex of *Pax6^-/-^* mutant embryos contains large subpial ectopias composed of GABAergic INs ([@B108]). These ectopias develop from E15.5 onward and express markers of LGE-derived INs, including Sp8, rather than markers of MGE-born INs, such as Lhx6. Their development parallels a progressive ventralization of the dorsal telencephalic VZ in *Pax6^-/-^* mutant embryos. At the start of neurogenesis (E12.5--E13.5) the most ventrolateral part of the *Pax6^-/-^* mutant cortex ectopically expresses the ventral telencephalic markers Ascl1 and Gsh2. As neurogenesis progresses ventral telencephalic identities extend dorsally such that by E14.5 most of the dorsal telencephalic VZ exhibits ventral characteristics. This progressive ventralization is accompanied by a dorsal shift in expression of markers of GABAergic INs such as Dlx1/2 and GAD67. Importantly, the INs that form the ectopias are derived from Emx1-expressing cortical progenitors which normally generate glutamatergic neurons, demonstrating that in *Pax6^-/-^* mutant mice, cortical progenitors are re-specified to generate GABAergic INs instead of glutamatergic neurons ([@B108]).

Dlx1/2, Ascl1, and Gsh2 have been shown to promote GABAergic fate, such as the expression of Gad67 ([@B116],[@B117]; [@B207]). Thus it is possible that Pax6 normally represses GABAergic identities in the cortex by blocking the expression of these TFs.

In *Pax6^-/-^* embryos, early born CP neurons are correctly specified as dorsal telencephalic neurons, expressing dorsal markers Math2 and Tbr1 ([@B173]). They fail, however, to adopt a correct glutamatergic phenotype. Interestingly, these early born neurons are not GABAergic either ([@B173]). Thus, during early corticogenesis, Pax6 participates in the specification of a correct glutamatergic phenotype but is not required to suppress GABAergic identities. [@B173] analyzed double mutants for Ngn1 and Ngn2, and showed that, during early stages of corticogenesis (E13.5), neurogenins are required to specify a glutamatergic, cortical phenotype, and repress GABAergic identities. Conversely, cortical neurons born at later stages of corticogenesis (E15.5) acquire a normal cortical and glutamatergic phenotype in *Ngn1^-/-^; Ngn2^-/-^* double mutants whereas in *Pax6^-/-^* embryos and in mutants lacking the orphan nuclear receptor Tlx, they express reduced levels of cortical and glutamatergic markers, compared to controls, and instead acquire a subcortical, GABAergic phenotype ([@B173]). This study shows that distinct genetic programs operate during early and late corticogenesis to specify cortical regional identity and neurotransmitter fate: neurogenins are required during early stages while Pax6 and Tlx are required during later stages of corticogenesis ([@B173]).

Pax6 Confers Laminar Fate
=========================

Throughout corticogenesis, newborn neurons migrate to the CP in an inside-out sequence such that deep layers are formed first and superficial layers form later. The final laminar position and subtype of cortical projection neurons is dependent on the time at which progenitors exit the cell cycle. In *Pax6^-/-^* mutant embryos, the SVZ and superficial cortical layers are defective, as shown by absence of expression of Svet1 (which marks the SVZ and superficial layers), while the VZ and deep CP layers are unaffected, as shown by the expression of Otx1 ([@B195]).

Examination of cortical lamination in *Ngn1^-/-^*; *Ngn2^-/-^* mutants showed that the expression of markers of deep cortical layers is reduced (Tbr1, Er81) while markers of superficial layers are expressed normally, indicating that late-born cortical neurons are correctly specified ([@B173]). In contrast, no defects are detected in the deeper cortical layers of *Pax6^-/-^*, *Tlx^-/-^*, or *Pax6^-/-^*;*Tlx^-/-^* double mutants. Markers of upper layers, however, are downregulated in Pax6 and Tlx single mutants and completely lost in *Pax6^-/-^*;*Tlx^-/-^* embryos suggesting that Pax6 and Tlx cooperate to specify the identity of late-born cortical neurons ([@B173]).

Study of cortical lamination in *Pax6^-/-^* mutants is limited by the fact that they die perinatally while cortical neurons do not reach their final location until around postnatal day 8 (P8). Therefore, more recent studies on the role of Pax6 in cortical lamination have used conditional mutants in which *Pax6* is inactivated specifically in the cortex and at later stages of cortical development and which survive postnatally. When *Pax6* was deleted specifically in the cortex from the onset of corticogenesis, markers of superficial layers were either downregulated or lost completely ([@B201]). In contrast, when *Pax6* was deleted in RGCs after the generation of deep cortical layers (between E14.5 and E16.5) using an hGFAP-cre transgenic line, the specification and number of late born neurons was unaffected ([@B201]), leading to the conclusion that Pax6 is not required for the specification of late born cortical neurons and that the defects of superficial layers observed in *Pax6^-/-^* and *Pax6*cKO mutants are a result of earlier defects in RGC proliferation. In a more recent study, [@B62] used an *Emx1-creErT2* transgenic line to remove Pax6 specifically in the cortex between E12.5 and E13.5, before superficial layer neurons are born. The resulting cKO mutant brains showed a dramatic reduction in the thickness of the superficial cortical layers, compared to control embryos. Late-born neurons were birth-dated by injecting BrdU at E15.5 and stained for expression of Cux1, a marker of upper layer (II to IV) pyramidal neurons. There was a substantial reduction in the number of E15.5 born neurons in the superficial cortical layers of the *Pax6-cKO* mutants and many fewer late-born neurons expressed Cux1 ([@B62]), indicating that Pax6 plays a crucial role in generation and specification of late born cortical neurons. Note that Pax6 protein was lost slightly earlier in the conditional mutants generated by [@B62] than in those used by [@B201], potentially explaining the difference in outcomes between the two studies.

Direct Transcriptional Targets of Pax6 Regulate Basal Progenitor Genesis, Neurogenesis, and Cell Fate Specification
===================================================================================================================

Pax6 exerts many of its effects, at least in part, by directly regulating the expression of specific target genes (**Table [1](#T1){ref-type="table"}**). As described above, work in the mouse has shown that Pax6 expressing APs that give rise to BPs transiently express the proneural TF Neurogenin 2 (Ngn2). BPs do not express Pax6 but do express the TF Tbr2. Loss of Pax6 function results in loss of Ngn2 expression in the cortical VZ and downregulation of Tbr2 in the SVZ ([@B190]; [@B198]; [@B222]; [@B169]; [@B86]; [@B162]; [@B168]), suggesting that the development of BPs is impaired. Conversely, Pax6 overexpression results in a marked increase in both Ngn2 and Tbr2 expression ([@B169]; [@B168]), each of which have been shown to be directly regulated by Pax6 ([@B169]; [@B168]; [@B199]). [@B169] showed that Pax6 directly binds and regulates the activity of the E1 enhancer of *Ngn2*, which regulates *Ngn2* expression in the cortex and the ventral spinal cord.

Another direct target that is positively regulated by Pax6 is the anti-neurogenic transcriptional co-repressor Tle1, a member of the Groucho/transducin-like enhancer of split (Gro/Tle) family ([@B167]; [@B199]). Gro/Tle proteins are expressed in proliferating neural progenitor cells where they promote maintenance of the undifferentiated state by inhibiting/delaying neuronal differentiation ([@B23]; [@B91]).

Pax6 also directly inhibits the expression of Olig2 ([@B89]), a TF critical for glial cell fate determination ([@B128]). Olig2 is expressed in a subset of cells in the rat neonatal SVZ, which differentiate into glia. Forced expression of Pax6 in these Olig2+ cells, using a retrovirus, caused downregulation of Olig2 and a shift toward neuronal fate ([@B89]). These authors showed that Pax6 can directly bind to Olig2's promoter and repress its activity.

Pax6 directly regulates markers of specific neuronal subtypes including Er81 and Cux1 ([@B202]; [@B167]; [@B199]). Er81 is a TF expressed in cortical progenitors, in a rostrolateral-high to caudomedial-low gradient, and in a subset of pyramidal cells scattered through layer 5 ([@B221]; [@B202]). In the absence of Pax6, cortical progenitors do not express Er81 and the rostrolateral cortex lacks Er81 positive layer 5 neurons. Cux1 is a marker of upper layer (II to IV) pyramidal neurons and functions as a negative regulator of dendritic complexity for these neurons ([@B35], [@B34]; [@B115]). As mentioned above, loss of Pax6 results in a dramatic reduction of Cux1+ upper layer neurons, suggesting that the specification of late born neurons is impaired ([@B62]).

How does a single gene exert such a wide range of biological effects? Part of the answer to this question is suggested by the findings that the Pax6 protein contains two distinct DNA-binding domains, one of which is regulated by alternate splicing and that Pax6 is able to interact with a number of co-factors, which influence its activity. This issue is discussed in the next section.

Complexity of Pax6 DNA-Binding Properties and its Distinct Functions
====================================================================

Pax6 binds to target DNA sequences through one or both of two DNA-binding domains, the paired domain (PD) and the homeodomain (HD; [@B17]; [@B92]; [@B174]; [@B179]). Transcriptional regulation of Pax6 target genes is mediated by a carboxy terminal proline/serine/threonine (PST) rich transactivation domain ([@B180], [@B178]; [@B194]; **Figure [7](#F7){ref-type="fig"}**).

![Schematic representation of functional domains in Pax6 and Pax6(5a) and their "optimal" DNA binding sites. **(A)** Pax6 and Pax6(5a) differ in a 14 amino acid insertion in the PAI subdomain. **(B)** "Optimal" DNA-binding sites for Pax6 PD, PD5a and HD. P6CON and 5aCON sequences were generated by selection procedure ([@B49]). P6CON is recognized by monomeric PD, while 5aCON contains four binding sites for PD5a that can bind up to four PD5a units. The "optimal" binding site of Pax6 HD is a dimer with typical HD binding sequences (ATTA/TAAT) separated by three nucleotides (G/T)CG ([@B37]).](fncel-09-00070-g007){#F7}

The PD is an evolutionarily conserved 128 amino acid DNA-binding domain shared by all members of the paired box (Pax) family of TFs (Pax1-Pax9; [@B28]; [@B69]). The Pax6 PD can be structurally and functionally separated into two independent DNA-binding globular helix-turn-helix subdomains, PAI and RED ([@B161]; [@B39]; [@B92]; **Figure [7A](#F7){ref-type="fig"}**). The well-established DNA-binding motif for canonical Pax6 PD, known as P6CON, is a bipartite 20 base pair DNA sequence whose 5^′^-half is recognized by the PAI subdomain and 3^′^-half by the RED subdomain ([@B39]; [@B49]; **Figure [7A](#F7){ref-type="fig"}**). The crystal structure of the Pax6 PD -- P6CON complex revealed direct interactions between both PAI and RED subdomains, the linker regions of PAI and RED subdomains and the N-terminal β-turn subdomain with individual bases and phosphate residues of cognate DNA ([@B39]; [@B49]; [@B217]). Pax6 also contains an internal, paired-type HD ([@B38]; [@B46]) which binds DNA in the form of a homodimer recognizing a symmetric binding site ([@B211]; [@B46]; [@B135]; **Figure [7B](#F7){ref-type="fig"}**).

Although different Pax6 DNA-binding domains can independently bind to their "optimal\" binding sites, using individual consensus binding motif to predict and confirm candidate Pax6-binding sites has proven to be very difficult ([@B177]; [@B205]; [@B212]). Unlike sequence specific DNA-binding proteins which harbor only one DNA-binding domain, Pax6 exhibits increased DNA-binding complexity because of its multiple DNA-binding subdomains (PAI, RED, and HD) which can be used in varying combinations when binding to DNA ([@B36]; [@B67]). A recent study further reinforced the complexity of Pax6 DNA-binding properties by systematically examining coordinated actions of different Pax6 binding subdomains and identified a number of novel variants of Pax6 DNA-binding motifs which can be bound by different combinations of Pax6 binding subdomains ([@B215]). As Pax6 can function either as a transcriptional activator or repressor ([@B212]), it is possible that some of these binding motif variants may induce structural changes in Pax6 proteins that enable them to switch their function between transcriptional activation and repression.

The complexity of the DNA binding properties of different Pax6 subdomains implies that the subregions exert distinct functions during embryonic cortical development. Pax6 mutant mouse lines with disruption of either the PD or the HD have been used to investigate the impact of different Pax6 binding domains on telencephalic development. [@B75] showed that the PD alone is necessary and sufficient for the regulation of most aspects of telencephalic development including neurogenesis, progenitor cell proliferation, and patterning in the developing cortex. In contrast, HD-specific mutations affected only subtle aspects of telencephalic development, such as establishment of the PSPB, and had no obvious effect on neurogenesis or proliferation ([@B75]). This suggests that the majority of Pax6's effects during telencephalic development are mediated by the PD with potentially different contributions by its subdomains. A recent study further dissected the roles of the different subdomains of the Pax6 PD during telencephalic development by examining mice with point mutations in its individual subdomains PAI and RED ([@B206]). This showed that both PAI and RED act largely in a redundant manner in patterning of the telencephalon, with only the PAI mutation resulting in the ectopic expression of subpallial genes such as *Gsx2* and *Olig2* into the pallium, suggesting that RED subdomain on its own is not sufficient to regulate telencephalic patterning. In addition, neurogenesis was affected only by the PAI subdomain mutation, phenocopying the neurogenic defects observed in full *Pax6^-/-^* mutants. Strikingly, this study also revealed that subdomains of Pax6 PD have distinct roles in regulating cortical progenitor cell proliferation, with mutations affecting the PAI and RED subdomains respectively reducing and increasing the number of mitoses.

Alternatively Spliced Isoforms of Pax6 and their Functions
==========================================================

In addition to Pax6 and Pax6(5a) a number of other splice variants of Pax6 have been reported, named p43, p33 and p32, each of which is less abundant and mostly localized in the cytoplasm ([@B26]; [@B90]; [@B156]). The 14 amino acid insertion in Pax6(5a) destroys the DNA-binding capacity of the PAI subdomain, leaving the RED subdomain of the PD and the intact HD for DNA binding ([@B49]; [@B107]). The PD in Pax6(5a) binds to a distinct DNA sequence from that bound by the canonical Pax6 PD, that has been named 5aCON ([@B49]). Direct comparison of the DNA binding sites recognized by Pax6 PD and PD(5a) showed partial sequence homology between the 3' halves of P6CON and 5aCON ([@B49]; [@B44], [@B43]). This homology allows Pax6 (which contains the canonical PD) to bind to both P6CON and 5aCON sites, whereas Pax6(5a) can only interact with the 5aCON site ([@B49]).

The majority of published molecular studies have focused on Pax6, as it contains the canonical PD and appears to be more abundant than Pax6(5a) ([@B26]; [@B165]; [@B106]). During early development, *Pax6* and *Pax6(5a)* transcripts are expressed in a ratio of 8:1 in the mouse forebrain, falling to 3:1 between E12.5 and E14.5 ([@B107]; [@B156]). A reduced ratio between Pax6 and Pax6(5a) was also seen during chick retina development ([@B8]). *PAX6* and *PAX6(5a)* transcripts are equally abundant in the human adult lens epithelium and cornea, as well as in monkey retina ([@B226]). These findings raise the possibility that expression of the two main Pax6 isoforms are regulated in a tissue- and temporal-specific manner, thereby affecting which target genes they recognize.

Although Pax6 and Pax6(5a) are commonly co-expressed, there is evidence that they exert distinct functions during embryonic development. For example, overexpression of either Pax6 or Pax6(5a) in chick retina showed that both isoforms led to increased retinal progenitor cell proliferation, but Pax6(5a) induced ectopic differentiation of the retina to a stronger degree than Pax6 ([@B8]). Similarly, Pax6(5a) strongly induces neural differentiation of murine embryonic stem cells *in vitro*, while Pax6 does not have such a strong effect ([@B176]). In the embryonic mouse forebrain, the different roles of the two Pax6 isoforms in regulation of cell proliferation and differentiation were also established from studies of Pax6 mutants. It was shown that mutations that abolish the binding property of the PD affect both proliferation and differentiation, while a PD(5a) mutation only affects proliferation and has no effect on cell fate/differentiation in mouse developing telencephalon ([@B75]). In a more recent study, Pax6(5a) specific target genes were identified through microarray analyses of gene expression profiles in cell lines stably expressing either Pax6 or Pax6(5a) ([@B99]). This revealed that a number of genes involved in cell proliferation, differentiation, and migration are differentially regulated by Pax6 and Pax6(5a), providing a potential molecular basis by which Pax6 and Pax6(5a) could exert their distinct biological functions.

Co-Factors Influence Pax6's Direct Regulation of Target Genes Involved in Embryonic and Adult Neurogenesis
==========================================================================================================

It is becoming clear that transcriptional regulation is highly dependent on the molecular and cellular context, one reason for which is that TFs do not act on their own but are dependent on interactions with other co-factors to exert their functions ([@B149]; [@B209]). These interactions introduce more specificity into the regulatory function of a given TF in a particular cellular context. A number co-factors that can interact with Pax6 have been identified. For example, Pax6 cooperates with Sox2 to target the lens-specific enhancer of the δ*-crystallin* gene ([@B94]); with MDIA to influence Pax6's functions in cerebellar granule cells ([@B196]); with Trim11 to mediate Pax6 degradation through the ubiquitin proteasome system (UPS) and modulate Pax6 transcriptional activity ([@B32]; [@B203]). More recently, Brg1/Brm associated factors complex (BAF) and Meis2 have been identified as two new co-factors that affect Pax6's direct regulation of target genes expression, in turn regulating its role in both embryonic and adult neurogenesis ([@B146]; [@B199],[@B200]; [@B1]).

BAF Complex
===========

A number of chromatin remodeling factors are known to play an important role during mammalian neural development, including the BAF complex ([@B84],[@B85]; [@B214]; [@B220]; [@B199],[@B200]). Interestingly, the function of the BAF complex in regulating neural development is dependent on its subunit composition. In mammals, BAF complexes contain two ATPase subunits Brg1 or Brm (Brahma), which are mutually exclusive and essential for remodeling activity, in combination with at least 15 different BAF (Brg1/Brm-associated factor) subunits ([@B84]; [@B181]). Certain BAF subunits have restricted expression patterns and thus could define tissue- or cell-type-specific BAF complexes. For example, the composition of BAF complexes in ES cells (esBAF) is defined by the incorporation of Brg1 but not Brm, BAF155 but not BAF170, and BAF60A but not BAF60C (**Figure [8](#F8){ref-type="fig"}**; [@B84],[@B85]). However, during the transition from ES cells to neural progenitors, the composition of BAF complexes is correspondingly changed, defining the neural progenitor specific BAF complex (npBAF; [@B111]; [@B219]; [@B84]). This process is accompanied by induction of BAF170 expression, replacing one of the BAF155 subunits and the recruitment of Brm as the ATP-ase subunit in the npBAF complex.

![Changes in subunit composition of BAF complexes during differentiation from ES cells to neural progenitor cells. BAF complexes undergo progressive changes in subunit composition during the transition from embryonic stem cells (ESCs) to neural progenitor cells (NPCs). The BAF complex in ESCs is called esBAF; in neuronal progenitors, npBAF. As ESCs differentiate into NPCs, The esBAF complexes incorporate Brm and BAF170, while excludes BAF60B and BAF155, thereby forming the neural progenitor-specific BAF (npBAF) complexes in NPCs.](fncel-09-00070-g008){#F8}

In two recent studies, [@B199],[@B200]), described an elegant model in which time-specific binding of BAF subunits including BAF170, BAF155, and Brm-ATPase to Pax6 modulates the expression of Pax6 target genes (*Tbr2, Cux1,* and *Tle1*) involved in the specification and generation of BPs and upper layer neuronal fate in the developing cortex. Interestingly, this model involves competition between BAF170 and BAF155 subunits in the BAF complex, which modulates chromatin modifications and binding of the Pax6/REST co-repressor complex to Pax6 target genes, thereby affecting their expression. During early neurogenesis (E12.5 to E14.5), the presence of BAF170 in the Pax6-BAF complex prevents the euchromatin state (a lightly packed form of chromatin) of the Pax6 target genes *Tbr2, Cux1* and *Tle1*, limiting the ability of Pax6 to bind them, thereby inhibiting their expression and promoting direct neurogenesis (RGCs directly give rise to neurons) at this developmental stage. In contrast, after E14.5 the expression of BAF170 decreases, accompanied by enhanced expression of BAF155, leading to a relaxed chromatin state of the promoters of the Pax6 target genes mentioned above, thereby enhancing their expression and in turn promoting indirect neurogenesis (RGCs indirectly give rise to neurons through generating BPs). This study provides novel insight into the interaction between BAF complex and Pax6 in the generation of BPs and the mode of neurogenesis in the developing cortex. In another recent study, [@B146] showed that Pax6 directly interacts with Brg1-ATPase of the BAF complex to modulate expression of genes involved in neuronal fate specification in adult neural progenitors. This study indicated that direct interaction of Pax6 with the Brg1/BAF complex enhances the expression of Pax6 target neurogenic TFs including *Sox11, Nfib,* and *Pou3f4* which form a cross-regulatory network driving neurogenic fate during adult neurogenesis. This study improved our understanding of Pax6-mediated adult neurogenesis and shed light on molecular mechanisms underlying the function of Pax6 in cell fate specification and conversion.

Meis2
=====

Meis2 belongs to the TALE (three amino acid loop extension) family of atypical HD-containing TFs. It can form heteromeric complexes with other transcriptional regulators to exert its functions during a range of biological processes ([@B143]; [@B29]; [@B104]; [@B141]). Meis proteins control cell cycle progression and cell fate specification of different stem and progenitor cell types in a variety of tissues including liver, heart, retina, and brain during development ([@B132]; [@B83]; [@B18]; [@B78]; [@B3]; [@B30]; [@B2], [@B1]; [@B153]). Recently the functional importance of Meis2 in adult neurogenesis has been discovered. It is involved in coordinated actions with Pax6 ([@B1]). During mouse adult neurogenesis, Meis2 is strongly expressed in the SVZ and rostral migratory stream (RMS) and in a subset of OB interneurons ([@B1]). [@B1] found that Meis2 can physically interact with Pax6 in cells in the SVZ and OB. This study also showed that the pro-neurogenic function of Pax6 in the adult SVZ requires direct interaction with Meis2. Meis2 has transcriptional activator function and [@B1] further confirmed that it acts as a Pax6 co-factor, binding to regulatory elements of the *Dcx* gene to promote its expression during adult SVZ neurogenesis.

Conclusion
==========

The TF Pax6 is one of the most intensively studied high-level developmental regulators, playing crucial roles in brain development and implicated in disease. Numerous studies, including those from our group, have shown that in both humans and mice many abnormalities resulting from mutations in *PAX6/Pax6* are in the cerebral cortex, where they arise largely because Pax6 is required for spatio-temporal control of many biological processes including cortical stem and progenitor cell proliferation and differentiation, neurogenesis, cell and laminar fate specification, neuronal migration, axon guidance and cortical arealization during early corticogenesis. However, we are a long way from having a comprehensive knowledge of exactly how Pax6 exerts such complex actions. In particular, there are at least three major challenges toward improved understanding of Pax6 functions. First, how does such highly complex expression pattern of Pax6 come about? As described above, the transcriptional regulation of *Pax6* is particularly complex and involves both short-range and long-range control mechanisms. Future studies are required to gain better knowledge of tissue- and time-specific regulatory elements responsible for spatiotemporally and quantitatively correct expression of Pax6. Secondly, how does Pax6 expression level influence its functional outputs? Our studies along with others have shown that Pax6 expression levels are crucial for its functions such as regulating progenitor cell proliferation and differentiation, and that mutations affecting Pax6 protein levels cause neurodevelopmental disorders in both humans and mice. Now it is time to ask exactly how Pax6 levels influence its actions at the molecular level. It will be of great interest to examine how varying levels of Pax6 influence its molecular actions at different cell cycle phases, which will be critical to obtain a clearer understanding of how Pax6 functions during the dynamics of cell division. Finally and probably most importantly, we are still far away from a comprehensive understanding of the complex gene networks that Pax6 regulates and how these networks change spatially and temporally during the course of cortical development. This represents a major challenge since Pax6 likely exerts direct and indirect regulation of different sets of downstream genes simultaneously, with context-dependent variation in the strength of their positive or negative effects.
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